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Abstract
In addition to acting as a hematopoietic growth factor,
interleukin-4 ( IL -4) inhibits growth of some trans-
formed cells in vitro and in vivo. In this study, we show
that insulin receptor substrate ( IRS) -1, IRS-2, and
signal transducer and activator of transcription 6
(STAT6) are phosphorylated following IL-4 treatment
in MCF-7 breast cancer cells. STAT6 DNA binding is
enhanced by IL-4 treatment. STAT6 activation occurs
even after IRS-1 depletion, suggesting the two path-
ways are independent. To examine the role of STAT6 in
IL-4–mediated growth inhibition and apoptosis, a full -
length STAT6 cDNA was transfected into MCF-7 cells.
Transient overexpression of STAT6 resulted in both
cytoplasmic and nuclear expression of the protein,
increased DNA binding in response to IL -4, and
increased transactivation of an IL-4 responsive pro-
moter. In STAT6-transfected cells, basal proliferation
was reduced whereas apoptosis was increased. Finally,
stable expression of STAT6 resulted in reduced foci
formation compared to vector- transfected cells alone.
These results suggest STAT6 is required for IL-4–
mediated growth inhibition and induction of apoptosis
in human breast cancer cells.
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Introduction
Interleukin-4 ( IL-4) is a pleiotropic immunoregulatory
cytokine that modulates cell surface receptor expression
and proliferation of B cells [28]. IL -4 acts through a multiunit
transmembrane receptor, IL-4R, which is a type II cytokine
receptor and lacks intrinsic kinase activity [14]. Binding of
IL-4, therefore, activates a signal transduction cascade
including the janus kinases Jak1 and Jak3, which phosphor-
ylate the cytoplasmic domain of the receptor as well as
downstream signaling molecules. Two main pathways are
activated in response to IL-4, the insulin receptor substrate-
2 ( IRS-2) pathway and the signal transducer and activator of
transcription 6 (STAT6) pathway [29]. Activation of IRS-2,
and IRS-1 in some cells, leads to association of the p85
subunit of PI -3 kinase and signals for mitogenesis and cell
survival [8,43]. Phosphorylation of STAT6 leads to formation
of STAT6 homodimers and subsequent translocation to the
nucleus. STAT6 binds to specific sequences in the promoters
of target genes and activates transcription of specific genes
including the IgE receptor in B cells [25].
Interestingly, IL-4R has been identified on the surface of
some solid tumors including murine sarcoma and adenocar-
cinoma cells [31], human renal, melanoma, ovarian [26,27],
lung [38], and breast carcinoma cells [27]. In addition, Mat et
al. [24] reported that IL-4R may be expressed by as many as
30% of primary breast tumor cells.
In contrast to its proliferative action in hematopoietic cells,
IL-4 has been shown to have antitumor activity both in vivo
and in vitro. Tepper et al. [35 ] found that tumor cells that were
engineered to secrete IL-4 failed to form tumors when
reintroduced into mice. Similarly, Golumbek et al. [10] found
that when IL-4 was transfected into cells derived from a
spontaneously arising murine renal carcinoma, expression of
IL-4 blocked tumor formation. This observation extended to
subsequent challenges with parental, non–IL-4 secreting
cells. These results suggested that IL-4 was mediated a host
immune response. However, in vitro experiments also
demonstrated that IL-4 directly inhibited the growth of
transformed cells including breast, colon, lung, renal, and
melanoma carcinoma cell lines in culture [2,26,27,36,37]. In
addition, we have previously shown that IL-4–mediated
growth inhibition of breast cancer cells is associated with
induction of apoptosis [12]. The signaling pathway respon-
sible for growth inhibition of breast cancer cells has not been
fully defined.
The observation that IL-4 treatment inhibits tumor cell
growth suggests key molecules in the transduction of the
inhibitory signal may be useful in breast cancer therapies. In
colon cancer and Burkitt’s lymphoma cell lines, it has been
suggested that IL-4 induction of STAT1 is responsible for cell
growth inhibition [5]. In breast cancer cells, it has been
shown that both IRS and STAT6 signaling are required to
induce expression of enzymes involved in steroidogenesis
[7 ]. We and other groups have shown that activation of IRS-
1 is associated with IL-4–mediated growth inhibition
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[12,15,34]. In fact, Jackson et al. [15] found that MCF-7 and
other breast cancer cell lines express IRS-2, but activate
IRS-1 in response to IL-4. Interestingly, reduction of IRS-1
mRNA and protein levels in MCF-7 cells did not effect IL-4–
mediated growth inhibition [13]. Therefore, in this study, we
hypothesize that STAT6 mediates IL-4– induced growth
inhibition and induction of apoptosis. Because STAT6
activation has not been reported in conjunction with IL-4–
induced growth inhibition, we first characterized STAT6
activation and DNA binding in human breast cancer cell
lines. Next, we characterized the effect of overexpression of
STAT6 on cell localization, DNA binding, and transactivation
of an IL-4 responsive promoter. Finally, we evaluated the
role of STAT6 in IL-4–mediated growth inhibition and
apoptosis of MCF-7 breast cancer cells.
Materials and Methods
Materials
MCF-7 cells were provided by C. Kent Osborne (Baylor
College of Medicine, Houston, TX) and were maintained in
improved minimal essential medium ( IMEM, Gibco,
Bethesda, MD) plus phenol red supplemented with 5% fetal
bovine serum (Summit, Ft. Collins, CO). IL-4 was a gift from
Satwant Narula (Schering-Plough Research Institute, Kenil-
worth, NJ). IRS-1 and IRS-2 antibodies were from Upstate
Biotechnology (Lake Placid, NY), STAT6 Western blotting
antibody was from New England Biolabs (Beverly, MA), and
STAT6 antibody used in immunoprecipitation and super-
shifting was from Santa Cruz Biochemicals (Santa Cruz,
CA). All other reagents were from Sigma unless otherwise
noted. Mouse STAT6 (mSTAT6) cDNA [42] and pKB350luc
IL-4–responsive luciferase construct [40] were kind gifts
from Dr. Michael Berton (University of Texas Health Science
Center, San Antonio, TX). Antisense STAT6 (asSTAT6)
was created by subcloning mSTAT6 into pCDNA3.1 in the
reverse orientation. Dr. Paul B. Rothman (Columbia Uni-
versity Health Sciences, New York, NY) kindly provided the
STAT6(645) construct [23].
Western Blots and Immunoprecipitation
Total cellular protein was extracted using a buffer
containing 50 mM Tris–HCl pH 7.4, 2 mM EDTA, 1% NP-
40, 100 mM NaCl, 100 mM Na orthovanadate, 100 g/ml
leupeptin, 20 g/ml aprotonin, and 107 M phenylmethyl-
sulfonyl (PMSF). Fifty micrograms of total protein or 250 g
of protein immunoprecipitated overnight with antibody
followed by 4 hours incubation with protein A agarose was
separated by 8% SDS-PAGE.
Following transfer of proteins to nitrocellulose, the
membrane was incubated in 5% milk–TBST (0.15 M NaCl,
0.01 Tris–HCl, pH 7.4, and 0.05% Tween 20) and then
immunoblotted with anti–IRS-1 (1:1000), anti– IRS-2
(1:100), or anti -STAT6 (1:2500). HRP-conjugated goat
anti - rabbit secondary antibody was added at 1:2000 for IRS
blots and HRP-conjugated donkey anti -mouse secondary
antibody at 1:5000 was added for STAT6 immunoblotting.
Proteins were visualized by enhanced chemiluminescence
(Pierce, Rockford, IL).
Gel Shift
Nuclear extracts were prepared by lysing cells first in a
hypotonic buffer consisting of 10 mM HEPES, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 5 g/ml aprotonin, and
0.5 mM PMSF. Nuclear pellets were then briefly centrifuged
and resuspended in one half volume low-salt buffer (20 mM
HEPES, 1.5 mM MgCl2, 20 mM KCl, 25% glycerol, 5 mM
EDTA, 0.5 mM DTT, 20 g/ml leupeptin, 5 g/ml aprotonin,
and 0.5 mM PMSF) and one half volume high-salt buffer
(20 mM HEPES, 1.5 mM MgCl2, 0.12 M KCl, 25% glycerol,
5 mM EDTA, 0.5 mM DTT, 20 g/ml leupeptin, 5 g/ml
aprotonin, and 0.5 mM PMSF) for 30 minutes on ice.
Extracts were centrifuged for 30minutes at 48 and the protein
concentration of the resulting extracts was determined. Ten
micrograms of nuclear proteins were then added to a
reaction mixture containing 6 l buffer A (10 mM HEPES,
pH 7.9, 1.5 nM MgCl2, 0.2 mM PMSF, and 0.5 mM DTT)
containing 0.5 g poly DI /DC, and 12 l of sample extracts to
volume in buffer C (20 mM HEPES, pH 7.9, 20% glycerol,
0.2 mM EDTA, 100 mM KCl, 0.2 mM PMSF, and 0.5 mM
DTT). Two microliters of labeled probe corresponding to the
STAT6 binding site from the FcR1 gene promoter
(AGCTTGTATTTCCCAGAAAAGGGATC) was added at
room temperature for 15 minutes. Samples were run on
4% native acrylamide gels in 0.5% Tris–boric acid–EDTA
buffer for approximately 3 hours. Gels were then dried and
exposed to film overnight.
Immunofluorescence
MCF-7 cells were transfected overnight with 1 g of
pcDNA or mSTAT6 using Fugene transfection reagent
(Boehringer Mannheim, Indianapolis, IN) according to the
manufacturer’s instructions. The next morning, 10,000 cells
from each transfected dish were seeded into two wells of
an eight-well chamber slide and allowed to express for
48 hours. Slides were fixed with 70% methanol and allowed
to air dry for 15 minutes. Slides were then rehydrated in
PBS–0.1% BSA for 15 minutes followed by blocking with
anti -mouse immunoglobulin for 30 minutes at room temper-
ature. Ten micrograms per well of STAT6 antibody (New
England Biolabs) was added for 30 minutes at room tem-
perature, followed by three 5-minute washes with PBS–
0.1% BSA. Ten micrograms per well fluorescein-conjugated
anti -mouse secondary antibody was added for 30 minutes
at room temperature followed by three 5-minute washes
with PBS–0.1% BSA. Slides were prepared with Crystal
mount (Biomeda, Foster City, CA) and covered with glass
coverslips before examination by fluorescent microscopy.
Luciferase Assays
COS-7 cells were plated in triplicate in DMEM+5% FCS
at 2.5105 cells in six-well plates and transfected the next
day. Briefly, cells were washed once with PBS, and
transiently cotransfected with 1 g of pKB350luc construct
plus 0.1 g of pSV -gal using Fugene transfection reagent
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(Boehringer Mannheim) according to the manufacturer’s
instructions. For some experiments, increasing amounts of
mSTAT6 cDNA plus empty vector to normalize the total
amount of DNA were transfected along with 0.1 g of pSV -
gal using Fugene transfection reagent. Transfected DNA
was left on cells overnight. The next morning, media were
changed to control medium or medium containing 50 ng/ml
IL-4 for 24 hours. Cells were harvested and luciferase
activity was measured using the luciferase assay system
(Promega, Madison, WI) according to the manufacturer’s
instructions.  -Gal activity was measured as described by
Rouet et al. [33]. To correct for differences in transfection
efficiency, luciferase values were divided by the appropriate
 -gal value in the same sample to achieve relative luciferase
units.
Single-Cell Proliferation Assay
The single-cell proliferation assay used in this study was
previously described [16,21]. MCF-7 cells were plated in
DMEM+5% FCS at 2.5105 cells per well in six -well plates
and transfected the next day. Cells were washed once with
PBS, and transiently cotransfected with 5 g of each
expression construct plus 0.5 g of pSV -gal using Fugene
transfection reagent according to the manufacturer’s instruc-
tions. Transfected DNA was left on cells overnight. The next
day, each well was divided into two 10-cm plates and
allowed to recover overnight. The next morning, media were
changed to control (SFM) or 10 ng/ml IL-4 for 48 hours.
Figure 1. IL -4 treatment results in phosphorylation of IRS -1, IRS -2, and
STAT6 in MCF-7 breast cancer cells. (A ) MCF-7 cells were untreated (  )
or treated with IL - 4 (10 ng /ml ) ( + ) for 10minutes. Total cell lysates ( total ) or
immunoprecipitate lysates ( IRS -1, IRS -2, and STAT6 ) separated by SDS-
PAGE and then immunoblotted with anti - phosphotyrosine antibody. Total cell
lysates were also immunoblotted with antibodies to IRS -1, IRS -2, and STAT6
to show the amount of representative protein in the lysates ( lower panels ).
Data shown are representative of three independent experiments. (B ) To
degrade IRS -1, MCF -7 cells were incubated in SFM in the absence (  ) or
presence ( + ) of IGF - I for 24 hours. Cells were then treated with IL -4 ( 10 ng /
ml ) for 10 minutes and levels of IRS -1 and STAT6 in total cell lysates were
determined by immunoblotting. Phosphorylated STAT6 was detected by
immunoprecipitation with anti -STAT6 antibody followed by anti - phosphotyr-
osine immunoblotting. Data shown are representative of three independent
experiments.
Figure 2. STAT6 DNA binding activity is induced by IL - 4 in breast cancer cell
lines. (A ) MCF-7 cell nuclear extracts were incubated with labeled probe
corresponding to the STAT6 binding site in the Fc1 gene promoter. Anti -
STAT6 or irrelevant antibodies ( anti -ER ) were added to the same reactions
to produce a supershifted complex. (B ) Breast cancer cells were treated with
IL - 4 ( 10 ng /ml ) for 30 minutes. Nuclear extracts were isolated and 10 g of
protein were incubated with labeled probe. Data shown are representative of
three independent experiments.
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Cells were then washed with 1 PBS, fixed in 3.7%
formaldehyde for 15 minutes at room temperature, and then
incubated in X-gal buffer overnight. Buffer was removed and
cells were washed three times with 1 PBS and then cells
were examined by microscopy.
Focus Formation Assay
MCF-7 cells were plated at 1.0106 cells per 10-cm dish
and transfected the next day. Ten micrograms total of DNA
(pcDNA or mSTAT6) was transfected. The next day, cells
were transferred to 150-cm dishes and allowed to adhere
overnight. The following day, selection was begun using 450
ng/ml G418. Selection was continued for 3 weeks and then
resulting foci were stained with 0.1% crystal violet.
Results
Activation of Signaling Molecules by IL-4 in Human Breast
Cancer Cells
We first examined which signaling molecules were
activated by IL-4 in human breast cancer cells. Treatment
of MCF-7 cells with IL-4 resulted in detection of an
approximately 180-kDa tyrosine phosphorylated protein in
total cell lysates (Figure 1A. ). As this band is similar in size to
the IRS proteins, we immunoprecipitated both IRS-1 and
IRS-2 from whole-cell lysates and then used anti -phospho-
tyrosine immunoblotting to detect phosphorylation. We found
that IRS-1 is heavily phosphorylated whereas IRS-2 is only
minimally phosphorylated after IL-4 treatment (Figure 1A ).
This is in contrast to hematopoietic cells where IL-4
treatment predominantly activates IRS-2 [41], but consis-
tent with the previous finding that IRS-1 is the predominant
substrate for IGF-I, insulin, and IL-4 in ER positive breast
cancer cells [15]. In addition to IRS-1 and IRS-2, IL-4 has
been reported to activate the transcription factor, STAT6.
Therefore, we examined activation of STAT6 by immuno-
precipitation followed by anti -phosphotyrosine immunoblot-
ting. We found that IL-4 treatment resulted in activation of
STAT6 in MCF-7 cells (Figure 1A ). Treatment of MCF-7
cells with IL-4 did not cause changes in the level of total
IRS-1, IRS-2, or STAT6 (Figure 1A ).
As both IRS-1 and STAT6 have been reported to
interact with the IL-4R chain [29], we next determined if
activation of IRS-1 and STAT6 by IL-4 was independent of
one another. We took advantage of a previous observation
in our laboratory that IGF-I treatment can induce degrada-
tion of IRS-1 within 24 hours [19]. To reduce levels of IRS-
1, we pretreated MCF-7 cells in serum-free media
(SFM) alone or SFM plus IGF-I for 24 hours and then
exposed the cells to IL-4 for 10 minutes. IRS-1 protein
levels were analyzed by immunoblotting and found to be
decreased to an undetectable level by IGF- I treatment
(Figure 1B ). STAT6 phosphorylation by IL-4 in the
Figure 3. STAT6 overexpression increases IL - 4–mediated DNA binding and
promoter activity. (A ) STAT6 expression was detected by immunofluores-
cence with anti -STAT6 antibody followed by fluorescein - conjugated anti -
mouse secondary antibody in untransfected MCF-7 cells ( a ) and cells
transfected with pcDNA (b ) or mSTAT6 (c ). Cells overexpressing mSTAT6
are indicated with arrows. Data shown are representative of three independent
experiments. Equal magnification ( 40 ) is shown in each panel. (B ) MCF-7
cells transiently transfected with 10 g pcDNA or mSTAT6 were treated with
increasing amounts of IL - 4. Nuclear extracts were prepared and then 10 g of
each nuclear extract was incubated with labeled probe. Data shown are
representative of two independent experiments. (C ) COS-7 cells were
transfected in triplicate with pKB350luc,  - gal expression construct, and
vector alone ( pcDNA ), wild - type mSTAT6, or antisense mSTAT6
(asSTAT6 ). After 12 hours, media was changed and cells were incubated
in the absence (  ) or presence ( + ) of IL - 4 ( 50 ng /ml ). Luciferase and  -
gal activities were determined 24 hours later. Results are expressed as
relative luciferase activity, which is defined as luciferase divided by  - gal
activity in the same sample. Error bars represent the mean of triplicate
samples±SEM. (D ) Increasing amounts of mSTAT6 were transfected in
triplicate into COS-7 cells treated with IL - 4 (50 ng /ml ). Luciferase was
measured and normalized to  - gal activity in the same samples. Error bars
represent the mean of triplicate samples±SEM. Data shown are representa-
tive of three independent experiments.
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absence of IRS-1 was then determined by immunopreci-
pitation of STAT6 followed by anti -phosphotyrosine immu-
noblotting. Phosphorylated STAT6 protein was detected
following IL-4 treatment either in the presence or absence
of IRS-1 (Figure 1B ). In addition, phosphorylated STAT6
protein was detected in MDA-MB-231 and MDA-MB-435A
cells, neither of which phosphorylate IRS-1 in response to
IL-4 (data not shown).
Characterization of STAT6 Expression and Activation in
Breast Cancer Cells
We have previously shown that inhibition of IRS-1 protein
by antisense expression reduced IGF-I–mediated prolifer-
ation and protection from apoptosis but had no effect on IL-
4–mediated growth inhibition [13]. Because IL-4 treatment
induced phosphorylation of STAT6 in addition to IRS-1, we
speculated that STAT6 might function to mediate IL-4–
induced growth effects in breast cancer cells. To test this
hypothesis, we first examined IL-4–mediated STAT6 DNA
binding activity in breast cancer cell lines. We found that IL-4
treatment of MCF-7 cells resulted in the formation of a
protein–DNA complex, which was supershifted by STAT6
antibody, but not by an unrelated antibody to the ER
(Figure 2A ). As shown in Figure 2B, we then examined
STAT6 DNA binding in a panel of breast cancer cell lines and
found that IL-4 activated STAT6 binding in all cells tested
(although at a very low level in MDA-MB-435A cells ) and
that the level of activation was consistent with our previously
published result of IL-4R mRNA expression in the same cell
lines [12].
To examine the role of STAT6 in IL-4–mediated growth
effects, we transiently overexpressed a full - length murine
STAT6 cDNA (mSTAT6) in MCF-7 cells. STAT6 expression
was detected by immunofluorescence using anti -STAT6
antibody followed by a fluorescein-conjugated anti -mouse
secondary antibody. Cells either untransfected or trans-
fected with vector alone showed uniform staining, which was
primarily cytoplasmic (Figure 3A, panels (a ) and (b ),
respectively). Following transient transfection with mSTAT6
some cells showed intense staining in both the cytoplasm
and nucleus consistent with over expression of mSTAT6
(Figure 3A, panel (c ) ). Next, we determined if transient
overexpression of mSTAT6 affected IL-4–mediated STAT6
DNA binding in MCF-7 cells. Figure 3B shows that MCF-7
cells transiently transfected with vector alone (pcDNA)
respond to increasing amounts of IL-4 with increased
STAT6 DNA binding and overexpression of mSTAT6
dramatically increased the amount of IL-4–mediated STAT6
DNA binding.
To determine if overexpression of mSTAT6 resulted in
increased transactivation of an IL-4–responsive promo-
ter we examined transcriptional activation of murine 1
Figure 4. STAT6 mediates growth inhibition and apoptosis in MCF-7 cells.
(A ) MCF -7 cells were transfected with pcDNA or mSTAT6 along with  - gal
expression construct as an indicator of transfection in a 10:1 ratio. Cells were
treated with IL -4 for 48 hours, fixed with 3.7% formaldehyde, and then stained
with X -gal to identify transfected cells. Colonies of blue cells were counted as
a measure of proliferation of transfected cells. Error bars represent the mean
of three independent experiments±SEM. **P<0.001 ( two -way ANOVA ) for
mSTAT6 control versus pcDNA control. (B ) Cells were transfected with
pcDNA, mSTAT6, or STAT6( 645 ) as described in (A ) and the percentage
of blue cells that had apoptotic morphology was measured. Error bars
represent the mean of three independent experiments±SEM. (C ) MCF-7
cells were transfected with pcDNA, mSTAT6, and then cultured in the
presence of neomycin for 3 weeks. Resulting foci were stained with 0.1%
crystal violet and then counted in triplicate. Error bars represent the mean of
triplicate counts±SEM. Data shown are representative of three independent
experiments. *P<0.05 (Student’s t - test ).
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immunoglobulin heavy-chain promoter cloned upstream of
firefly luciferase (pKB350luc). Figure 3C shows that addition
of IL-4 resulted in an approximate 1.6- fold induction of
relative luciferase activity when cells were transfected with
vector alone (pBL2 basic), presumably through activation of
endogenous STAT6. Transient overexpression of mSTAT6
enhanced IL-4–mediated induction and, conversely, tran-
sient transfection of antisense mSTAT6 (asSTAT6) resulted
in inhibition of both IL-4–induced and basal promoter
activity. Finally, in Figure 3D we show a dose-responsive
increase in activation corresponding to increased expression
of mSTAT6 in the presence of IL-4.
The Role of STAT6 in IL-4–Mediated Growth Inhibition and
Apoptosis
We next determined the role of STAT6 in IL-4–mediated
growth inhibition and apoptosis. Because transient trans-
fection of MCF-7 cells results in gene expression in a
relatively small percentage of transfected cells, we used a
single-cell proliferation assay that has been previously
described [16,21]. MCF-7 cells cotransfected with a  -
galactosidase expression vector and pcDNA alone (pcDNA)
or the mSTAT6 construct. After treatment with IL-4 for 48
hours, the cells were stained with X-gal, and colonies of blue
cells were examined for cell number. Cells transfected with
vector alone had a mean of 2.52±0.09 cells per colony,
representing roughly two doublings in the absence of IL-4
(control ) (Figure 4A ). IL-4 treatment significantly reduced
the mean number of blue cells per colony to 2.33±0.16
(P<0.05). Interestingly, expression of mSTAT6 alone
dramatically reduced the number of blue cells per colony
compared to pcDNA (1.20 vs. 2.52, P<0.001), and a small
additive effect due to IL-4 was observed.
Using the single-cell proliferation assay, we also exam-
ined the effect of overexpression of mSTAT6 on IL-4–
induced apoptosis. To do this, we determined the percent-
age of blue cells that were apoptotic based on morphologic
characteristics including reduced cytoplasm and chromatin
condensation. Figure 4B shows that cells transfected with
pcDNA responded to IL-4 with a two- fold increase in the
number of cells undergoing apoptosis. In contrast, trans-
fection of wild- type mSTAT6 resulted in a large increase in
the basal rate of apoptosis, which was only slightly further
increased by IL-4 treatment. To determine if inhibition of
STAT6 function would block IL-4 induced apoptosis, we
transfected cells with a dominant negative STAT6 construct
that lacks the transactivation domain (STAT6(645) ). This
construct inhibited transactivation of the murine 1 immuno-
globulin heavy-chain promoter and STAT6 DNA binding
induced by IL-4 (data not shown). Introduction of this
STAT6(645) dominant negative construct into these cells
eliminated IL-4– induced apoptosis.
Taken together, these results suggested that overexpres-
sion of STAT6 was responsible for IL-4 effects in MCF-7
cells. Furthermore, overexpression of mSTAT6 was capable
of inducing apoptosis in the absence of additional IL-4.
Therefore, the ability of mSTAT6 to inhibit the growth of
MCF-7 cells in a colony- forming assay was examined.
MCF-7 cells were transfected with pcDNA or mSTAT6 and
then foci were allowed to form for 3 weeks under G418
selection (Figure 4C ). Transfection of mSTAT6 significantly
inhibited the number of foci (P<0.05) compared to trans-
fection of vector alone. In contrast, STAT6(645) did not
influence colony number in this assay.
Discussion
We have shown that IL-4 treatment results in growth
inhibition and induction of apoptosis in human breast cancer
cells [12]. These growth effects are associated with
phosphorylation of two key components of distinct signaling
pathways, IRS-1 and STAT6. We find activation of these two
pathways occurs independently in breast cancer cells,
consistent with findings made in hematopoietic cells
[18,29]. Since we previously showed that inhibition of IRS-
1 failed to abrogate IL-4–mediated growth effects [13], we
hypothesized that STAT6 may be mediating these effects.
Inhibition of STAT6 function by a dominant negative
construct blocked the ability of IL-4 to induce apoptosis.
Moreover, overexpression of mSTAT6 alone inhibited pro-
liferation, increased the basal rate of apoptosis, and inhibited
focus formation of MCF-7 cells. These findings show that
STAT6 can induce apoptosis in breast cancer cells.
STAT6 is a cytoplasmic protein that dimerizes on
phosphorylation, translocates to the nucleus, and activates
transcription at specific promoter regions. There are several
places in this signaling pathway where STAT6 may act to
modulate cell survival. First, it is possible that STAT6 is
interacting with other cytoplasmic proteins to impact growth
or possibly cell death pathways. Although little is known
about STAT proteins acting as cytoplasmic signal trans-
ducers, it has been reported that there is some cross talk
between STAT proteins and the PI-3 kinase and Erk1/Erk2
MAPK pathways [1,9,30]. Unlike dimerization and transcrip-
tional activation, which depend on tyrosine phosphorylation,
interaction with these cytoplasmic pathways is associated
with serine phosphorylation. Alternatively, the effects
exerted by IL-4 in breast cancer cells may be due to
transcriptional control of growth- and or death- regulating
genes by STAT6. Consistent with this, Kaplan et al. [17]
reported that STAT6 can modulate the transcription of the
cyclin-dependent kinase inhibitor p27, thereby affecting cell
growth. Finally, STAT6 action may be due to the specific
nature of STAT6-mediated control of gene expression.
Unlike other transcription factors, STAT6-mediated induc-
tion of transcription is associated with class-switch recombi-
nation [22,32]. This form of recombination involves
introduction of double-strand breaks in the DNA followed
by recombination of immunoglobulin receptor -coding se-
quences mediated by switch recombinases and potentially
other proteins such as LR1 [4]. It is possible that
components of this pathway are not expressed by breast
cancer cells, resulting in STAT6-mediated transcription
coupled to DNA double-strand breaks but without resolution
of the recombination event, resulting in programmed cell
death.
Neoplasia . Vol. 4, No. 4, 2002
STAT6 is Required for IL-4-Induced Apoptosis Gooch et al. 329
The data presented here suggest that STAT6 over-
expression alone may be capable of inducing apoptosis,
which is a novel result. In the single-cell proliferation assay,
we observed a significant increase in the basal level of
apoptosis when mSTAT6 was expressed, which was further
increased in the presence of IL-4. It appears that STAT6
alone, in the absence of additional exogenous IL-4, is
capable of inducing apoptosis. There are several possible
explanations for this result. First, transient expression of
mSTAT6 in MCF-7 cells resulted in a dramatic increase in
IL-4–mediated STAT6 DNA binding (Figure 3B ); compare 1
ng/ml IL-4 in the pcDNA-transfected lane with 1 ng/ml IL-4
in the mSTAT6-transfected lane). There was no detectable
binding of STAT6 in the absence of IL-4, indicating that
overexpression alone is not sufficient for activation of STAT6
DNA binding and that MCF-7 cells likely do not produce IL-
4, consistent with previously published findings [36]. How-
ever, the dramatic increase in IL-4–mediated binding may
explain the inhibition of focus formation in full serum by
STAT6 overexpression observed in Figure 4C as full serum
may contain IL-4 in addition to many other cytokines and
growth factor.
In contrast to the previous findings by Chang et al. [5 ], we
were unable to demonstrate IL-4–induced activation of
STAT1 in breast cancer cells (data not shown). Whereas we
have shown that interferon  in breast cancer cells activates
STAT1 and causes growth inhibition [11], IL-4 is unable to
activate this pathway. As suggested by Chang et al.,
differences in STAT activation are likely responsible for the
different biologic effects of IL-4 in cells. It appears that IL-4
causes growth inhibition of both breast and colon cancer
cells despite activating different STAT pathways.
Due to toxicity observed in phase I and II clinical trials for
IL-4 [6,39], IL -4 may never be a feasible therapeutic agent,
despite its antitumor capabilities in vitro and in in vivo animal
models. Therefore, the signaling pathway required for IL-4–
mediated growth effects may be a source of novel
therapeutic targets. As such, it will be very important to
define what specific target genes are activated in response to
STAT6. As with many important signaling molecules in
breast cancer cells, including IGF- IR and IRS-1 [3,20], it will
be crucial to determine if there is prognostic significance
associated with STAT6 expression in human breast tumors.
These are important areas of future investigation that may
yield new therapeutic insights for regulating the growth of
breast tumors and potentially other human cancers.
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